Following on from information provided to NICE by the company in July 2018, the appraisal of Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 913

Email enquiries

External Assessment Group BMJ Evidence Centre, BMJ Group

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in July 2018, the appraisal of Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in July 2018, the appraisal of Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
17 December 2018 On 26 July 2018, the Committee for Medicinal Products for Human Use (CHMP) re-examined the opinion and confirmed the refusal of the marketing authorisation. Therefore this topic will remain indefinitely suspended on the NICE work programme.
09 April 2018 Suspended. On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Dexxience (betrixaban), intended for the prevention of venous thromboembolism in acutely ill medical patients. Consequently the first appraisal committee discussion of this topic has been cancelled and NICE have suspended the appraisal. We will continue to monitor any developments and will update interested parties if the situation changes.
19 March 2018 Following a regulatory update from the company we will not be proceeding with the committee discussion scheduled for 17 April 2018. We will provide a further update when more information is available.
03 November 2017 Invitation to participate
25 January 2017 Draft scope documents
05 December 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual